JP2012504619A - 肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法 - Google Patents

肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法 Download PDF

Info

Publication number
JP2012504619A
JP2012504619A JP2011530103A JP2011530103A JP2012504619A JP 2012504619 A JP2012504619 A JP 2012504619A JP 2011530103 A JP2011530103 A JP 2011530103A JP 2011530103 A JP2011530103 A JP 2011530103A JP 2012504619 A JP2012504619 A JP 2012504619A
Authority
JP
Japan
Prior art keywords
ghrelin
tat
subject
coa
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011530103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504619A5 (enExample
Inventor
エー． コール，フィリップ
ピー． バーネット，ブラッドリー
ホワン，ヨウサン
ディー． ボエケ，ジェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2012504619A publication Critical patent/JP2012504619A/ja
Publication of JP2012504619A5 publication Critical patent/JP2012504619A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011530103A 2008-10-03 2009-09-18 肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法 Withdrawn JP2012504619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10254908P 2008-10-03 2008-10-03
US61/102,549 2008-10-03
PCT/US2009/057512 WO2010039461A2 (en) 2008-10-03 2009-09-18 Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes

Publications (2)

Publication Number Publication Date
JP2012504619A true JP2012504619A (ja) 2012-02-23
JP2012504619A5 JP2012504619A5 (enExample) 2012-11-15

Family

ID=42074096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530103A Withdrawn JP2012504619A (ja) 2008-10-03 2009-09-18 肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法

Country Status (6)

Country Link
US (1) US8772229B2 (enExample)
EP (1) EP2340258A4 (enExample)
JP (1) JP2012504619A (enExample)
AU (1) AU2009298892A1 (enExample)
CA (1) CA2739418A1 (enExample)
WO (1) WO2010039461A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2011159917A2 (en) 2010-06-16 2011-12-22 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2015010210A1 (en) * 2013-07-24 2015-01-29 Bucio Alfonso Abizaid Compounds for regulating acylated ghrelin
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
KR102333926B1 (ko) * 2020-03-11 2021-12-02 연세대학교 산학협력단 Tat 펩타이드 변이체를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물
CN112014340A (zh) * 2020-09-01 2020-12-01 广西玮美生物科技有限公司 非人灵长类动物胃饥饿素的检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105381453B9 (zh) 2005-09-29 2019-01-11 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
US8013015B2 (en) * 2008-10-02 2011-09-06 Board Of Regents, The University Of Texas System Small molecule inhibitors of ghrelin O-acyltransferase

Also Published As

Publication number Publication date
EP2340258A2 (en) 2011-07-06
US8772229B2 (en) 2014-07-08
AU2009298892A1 (en) 2010-04-08
CA2739418A1 (en) 2010-04-08
WO2010039461A3 (en) 2010-07-01
US20110257086A1 (en) 2011-10-20
WO2010039461A2 (en) 2010-04-08
EP2340258A4 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
JP2012504619A (ja) 肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法
KR102578890B1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
AU2010259986B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR20170108936A (ko) 신규한 α4β7 펩타이드 단량체 및 이량체 길항제
JP5000663B2 (ja) 神経ペプチド２受容体アゴニスト
JP2009203235A (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
JP2011521919A (ja) Ｊｎｋシグナル伝達経路の細胞透過性のペプチド性阻害剤の、慢性または非慢性の炎症性消化器疾患の治療のための、使用
US20100016242A1 (en) Myosin light chain kinase inhibitors and methods of use
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
US11046739B2 (en) BH4 stabilized peptides and uses thereof
AU2012272550A1 (en) Prevention and treatment of acute inflammatory conditions
WO2020112565A1 (en) Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
EP4392051A1 (en) Leukocyte-specific cell penetrating molecules
JP5844971B2 (ja) コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド
EP4013442A1 (en) Treatment
KR20250160531A (ko) Ptp1b/nck1 상호작용 억제제 및 이의 제조 및 사용 방법
WO2025043563A1 (zh) 一种靶向生长抑素受体的肽、偶联药物及其应用
CN101305099A (zh) 具有提高的生物利用度的t3和t4的前药
US7879572B2 (en) Regulation of F1-ATPase beta subunit cellular location
JP2025521647A (ja) 選択的ｉｌ－２３受容体アンタゴニストとしての新規ペプチド
JPWO2007105442A1 (ja) 摂食障害または摂水障害の治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120912

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131204